Page 4 - Column Group News Today

The university’s $17.9 billion endowment has also invested directly in OpenAI and in OpenAI’s corporate venture fund, documents show.

(Bloomberg) -- Roche Holding AG agreed to pay as much as $3.1 billion for Carmot Therapeutics Inc., a developer of the new type of weight-loss treatments that’s sparked a pharma industry gold rush.Most Read from BloombergHow Suspects Laundered Billions in Singapore for YearsBonds Retreat as Doubts Over Rate Cuts Creep In: Markets WrapBitcoin Surges Past $42,000 as Crypto Rally Gathers SteamHere’s How to Invest in Gold as It Hits an All-Time HighAlaska Air Agrees to Buy Hawaiian in ...

Though Carmot’s drugs are still in early stages of development, the deal could lead to a competitor to the likes of Wegovy and Eli Lilly & Co.’s Zepbound.

BioPharma

Bloomberg Swiss drugmaker Roche agreed to pay as much as US$3.1 billion (HK$24.1 billion) for US weight-loss treatment developer Carmot Ther...

Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.

OpenAI’s corporate structure limits control from any of its shareholders.

/PRNewswire/ -- The "DNA Encoded Library: Platforms and Services Market (2nd Edition), 2023-2035" report has been added to ResearchAndMarkets.coms offering....

Key Insights Significantly high institutional ownership implies NGM Biopharmaceuticals' stock price is sensitive to...

Dr. McHutchison is a world-renowned physician, scientist, and drug developer who has led the research and development of numerous marketed therapies for...